Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levamfetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.95 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.95 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.95 |
| ▸ | MAOA | P21397 | 1/20 | 0.95 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.95 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.95 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.95 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextroamphetamine SCHEMBL1042914 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Levamfetamine SCHEMBL4070216 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL27581784 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL4070210 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL573665 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Dextroamphetamine SCHEMBL9114306 | 1.00 | SLC6A2 (0.95) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL15094242 | 0.97 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Amphetamine SCHEMBL1560962 | 0.97 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Levamfetamine SCHEMBL9673275 | 0.97 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| Dextroamphetamine SCHEMBL8859 | 0.97 | SLC6A2 (1.00) | SLC6A2TAAR1SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117654455-B | Purifying and extracting composition, kit and method for determining drugs and fentanyl drugs in biological sample | 宁波市疾病预防控制中心(宁波市健康教育与促进中心) | 2025-06-10 | — | — | CN | claimed |
| CN-118948849-A | Medicine for preventing and treating diseases related to anti-obesity effect | 盐野义制药株式会社 | 2024-11-15 | — | — | CN | claimed |
| CN-118225543-A | Method suitable for rapid enrichment of 34 kinds of psychotropic drugs in large-volume sewage | 宁波市疾病预防控制中心(宁波市健康教育与促进中心) | 2024-06-21 | — | — | CN | claimed |
| EP-3717452-B1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | SpecGx LLC (US) | 2024-06-05 | — | — | EP | claimed |
| CN-117654455-A | Purifying and extracting composition, kit and method for determining drugs and fentanyl drugs in biological sample | 宁波市疾病预防控制中心(宁波市健康教育与促进中心) | 2024-03-08 | — | — | CN | claimed |
| CN-114423436-A | Method for treating congenital adrenal hyperplasia | 云杉生物科学公司 | 2022-04-29 | — | — | CN | claimed |
| EP-3717452-A1 | PROCESS FOR PREPARING ACYLATED AMPHETAMINE DERIVATIVES | SpecGx LLC (US) | 2020-10-07 | — | — | EP | claimed |
| CN-107093559-B | Preparation of graphene electrode MoS based on Ni catalysis2Method of field effect transistor | 镇江市电子管厂 | 2019-12-24 | — | — | CN | claimed |
| US-8486448-B2 | Misuse preventative, controlled release formulation | PALADIN LABS INC. (CA) | 2013-07-16 | — | — | US | claimed |
| EP-2367541-A1 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION | Labopharm Inc. (CA) | 2011-09-28 | — | — | EP | claimed |
| WO-2003004009-A1 | PHARMACEUTICAL COMPOSITION | GENEVA PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | claimed |
| US-6500459-B1 | PHARMACEUTICAL COMPOSITION FOR CONTROLLED ONSET AND SUSTAINED RELEASE OF ACTIVE INGREDIENT COMPRISING CORE COMPRISING ACTIVE INGREDIENT, HYDROPHILIC CARRIER AND HYDRODYNAMIC DIFFUSION ENHANCER WITH FUNCTIONAL COATING MEMBRANE SURROUNDING CORE | CHHABRA HARINDERPAL (US) | 2002-12-31 | — | — | US | claimed |
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | MIDHA KAMAL K (CA) | 2002-05-16 | — | — | US | claimed |
| EP-1191924-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF (D-THREO)-METHYLPHENIDATE AND A SECOND CNS STIMULANT | Pharmaquest Limited (BM) | 2002-04-03 | — | — | EP | claimed |
| EP-1165054-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | Pharmaquest Limited (BM) | 2002-01-02 | — | — | EP | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| WO-2000059481-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| US-4952402-A | EDIBLE TASTE-MASKED DRUGS; MICROMATRIX ACTIVE MATERIAL COATED WITH NONTOXIC POLYMER; LIQUIDS; TABLETS | ELAN CORPORATION, P.L.C. (IE) | 1990-08-28 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058061-A1 | Pharmaceutical dosage form for pulsatile delivery of methylphenidate | SLC18A1, SLC6A3, CRH | SLC6A2 10/4885SLC6A3 2/4885TAAR1 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.